A Phase I Study to Determine the Safety and Pharmacokinetics of Intravenous Administration of SB743921 on a Once Every 3 Week Schedule in Patients With Solid Tumors.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 15 Oct 2008
At a glance
- Drugs SB 743921 (Primary)
- Indications B cell lymphoma; Solid tumours; T cell lymphoma
- Focus Adverse reactions
- 15 Oct 2008 Actual start date changed from Feb 2004 to Apr 2004 as reported by Clinicaltrials.gov.
- 15 Oct 2005 New trial record.